PRESS RELEASE published on 11/30/2023 at 14:30, 11 months 24 days ago Jaguar Health to Present December 5 at the MedInvest Oncology Investor Conference Jaguar Health, Inc. to present on Dec 5, 2023, at the MedInvest Oncology Investor Conference, discussing pivotal phase 3 OnTarget trial of crofelemer for prophylaxis of diarrhea in adult cancer patients receiving targeted therapy Crofelemer Jaguar Health Oncology Investor Conference Phase 3 Clinical Trial Cancer Therapy
PRESS RELEASE published on 11/21/2023 at 14:30, 1 year ago Top Line Data for Jaguar Health’s Pivotal Phase 3 OnTarget Trial for Prophylaxis of Diarrhea in Adult Cancer Patients Receiving Targeted Therapy Forthcoming
PRESS RELEASE published on 11/14/2023 at 14:00, 1 year ago Jaguar Health Reports Third Quarter 2023 Financial Results
PRESS RELEASE published on 11/10/2023 at 22:15, 1 year ago Jaguar Health Announces New Employee Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
PRESS RELEASE published on 11/09/2023 at 14:30, 1 year ago Breast Cancer Related Results of Groundbreaking Napo Pharmaceuticals (a Jaguar Health Family Company) Supported Study on Quality of Life for Cancer Patients and Survivors Accepted for Presentation at the December 2023 San Antonio Breast Cancer Symposium
PRESS RELEASE published on 11/08/2023 at 16:25, 1 year ago Jaguar Health Receives Additional 180-day Grace Period to Regain Compliance with Nasdaq's Bid Price Rule
PRESS RELEASE published on 11/08/2023 at 14:30, 1 year ago Jaguar Health to Hold Investor Webcast Tuesday, November 14th at 8:30 AM Eastern Regarding Q3 2023 Financials & Corporate Updates
PRESS RELEASE published on 11/07/2023 at 14:30, 1 year ago REMINDER: Jaguar Health to Host Virtual Educational Webinar on Rare Intestinal Failure Diseases with Leading Gastroenterologists and Nutrition Experts November 8th from 1:00 PM to 2:30 PM EST
PRESS RELEASE published on 11/02/2023 at 13:30, 1 year ago Jaguar Health Enters Exclusive Crofelemer Revenue Sharing License and Commercialization Agreement with Quadri Pharmaceuticals Store for Rare Intestinal Failure Diseases in Middle East Markets
PRESS RELEASE published on 11/01/2023 at 13:30, 1 year ago Issuance of New US Patent Bolsters IP Protection for Jaguar Health in the Treatment of Short Bowel Syndrome (SBS)
Published on 11/22/2024 at 23:55, 1 day 19 hours ago Boron One Announces Early Warrant Exercise Incentive Program
Published on 11/22/2024 at 23:30, 1 day 19 hours ago Electric Royalties Enters Into Definitive Agreement to Acquire 0.75% Gross Revenue Royalty on Producing Punitaqui Copper Mine in Chile
Published on 11/22/2024 at 23:05, 1 day 20 hours ago Nexa Resources Announces Closing Transaction of Pukaqaqa Project Sale to Olympic
Published on 11/22/2024 at 22:30, 1 day 20 hours ago Delaforce Energy Corp. Announces Acquisition of Bouchard Well Service Ltd.
Published on 11/22/2024 at 17:53, 2 days 1 hour ago Funding Circle Plc: POS-Transaction in Own Shares
Published on 11/22/2024 at 16:55, 2 days 2 hours ago EQS-Adhoc: Comment on withdrawn non-binding offer
Published on 11/21/2024 at 06:58, 3 days 12 hours ago Net Asset Value per share increases with 9.4% in six months to EUR 55.6 thanks to continued strong growth performance of the portfolio
Published on 11/20/2024 at 19:20, 3 days 23 hours ago Peugeot Invest Board of Directors to evolve following the May 2025 Annual General Meeting
Published on 11/20/2024 at 17:45, 4 days 1 hour ago MEDESIS PHARMA HAS COMPLETED ITS CLINICAL STUDY FOR THE TREATMENT OF ALZHEIMER'S DISEASE WITH NANOLITHIUM
Published on 11/20/2024 at 17:45, 4 days 1 hour ago Disclosure of Share Capital and Voting Rights Outstanding as of October 31, 2024
